| Stereochemistry | ACHIRAL |
| Molecular Formula | C10H12ClNO |
| Molecular Weight | 197.661 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
ClCCC(=O)NCC1=CC=CC=C1
InChI
InChIKey=JPYQFYIEOUVJDU-UHFFFAOYSA-N
InChI=1S/C10H12ClNO/c11-7-6-10(13)12-8-9-4-2-1-3-5-9/h1-5H,6-8H2,(H,12,13)
| Molecular Formula | C10H12ClNO |
| Molecular Weight | 197.661 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Beclamide (N-benzyl-B-chloropropionamide) is a drug that possesses anticonvulsant activity. It is no longer used. It has been used as a sedative and as an anticonvulsant. Beclamide has been used in the management of both epilepsy and behavioral disorders associated with epilepsy. It was introduced into clinical practice in 1952 under the brand names Hibicon, Lederle and later it was withdrawn. This agent was shown to be effective in grand mal but not absence seizures. Early claims emphasized its safety, and it is not entirely clear why it was withdrawn from therapy for epilepsy. Interest in the drug was rekindled in the 1990s as an adjunct in the treatment of schizophrenia.
CNS Activity
Originator
Approval Year
Sourcing
PubMed
Sample Use Guides
Adult Dosage: 7.14 to 14.28 mg/kg, p.o, Frequency - 8 hourly
Route of Administration:
Oral
Succinic semialdehyde dehydrogenase activity was inhibited by 10 to 20% at low concentrations (0.01 to 0.1 mM) of diazepam, carbamazepine, beclamide, acetazolamide, and di-n-propylacetate, and by 40% or more at high concentrations (2.5 to 10.0 mM) of diazepam, phenobarbital, carbamazepine, Beclamide, and di-n-propylacetate in mouse brain homogenates. Beclamide at 100 umol/l significantly inhibited K+-evoked release of D-aspartate.
